Trijardy XR —A New 3-Drug Combination for Type 2 Diabetes

This Medical Letter compares a newly approved fixed-dose combination pill comprising the sodium-glucose cotransporter 2 inhibitor empagliflozin, the dipeptidyl peptidase-4 inhibitor linagliptin, and extended-release metformin, with available formulations of each of the pill ’s individual components for oral treatment of type 2 diabetes in adults.
Source: JAMA - Category: General Medicine Source Type: research